Halozyme Therapeutics trades as part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Helen I. Torley. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
Previous Intraday Performance:
The HALO shares had a previous change of 2.97% which opened at 15.36 and closed at 15.62. It moved to an intraday high of 15.68 and a low of 15.12.
Over the last five trading days, HALO shares returned 4.90% and in the past 30 trading days it returned -4.76%. Over three months, it changed -9.29%. In one year it has changed -14.60% and within that year its 52 week high was 19.56 and its 52 week low was 13.24. HALO stock is 17.98% above its 52 week low.
Our calculations result in a 200 day moving average of 16.37 and a 50 day moving average of 16.13. Right now, HALO stock is trading -4.56% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
The company has a market cap of $2.3b with 145.5m shares outstanding and a float of 134.5m shares. Trading volume was 595,750 shares and has experienced an average volume of 803,306 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Halozyme Therapeutics was -0.55 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is 0.01.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-07-2019:||0.01|
|4th||Qtr 2018||Reported 02-21-2019:||-0.01|
|3rd||Qtr 2018||Reported 11-06-2018:||-0.19|
|2nd||Qtr 2018||Reported 08-07-2018:||-0.16|
|1st||Qtr 2018||Reported 05-10-2018:||-0.19|
Base on our calculations, the intrinsic value per share is 38.42, which means it might be undervalued and has a margin of safety of 59.34%.
The growth of the EPS is critical in understanding the current valuation of Halozyme Therapeutics; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -43.10% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 1.74.
Business Wire: Moog Reports Second Quarter Results
Based on last reported financials, the company’s return on assets is -11.05%, profit margin is -28.70%, price-to-sales is 12.41 and price-to-book is 8.49.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result